NIAID Project Nextgen aims to determine mucosal CoPs.
Gagne 2024 found that mucosal IgA responses to a mucosally administered bivalent adenovirus-vectored SARS-CoV-2 vaccine in NHPs correlated with protection in the upper airways, while both mucosal IgG and IgA, along with T-cell responses, were key for protection in the lungs.